|
|
Article: Nanobac Life Sciences, Inc. Announces International Journal of Pathophysiology Publication Demonstrating Reversal of Coronary Artery Calcification.
- Article from:
- PR Newswire
- Article date:
- July 29, 2004
CopyrightCOPYRIGHT 2004 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Nanobac Life Sciences, Inc. (OTCPK: NNBP), announced today the publication of a study titled "Calcification in Coronary Artery Disease Can Be Reversed by EDTA - Tetracycline Long-Term Chemotherapy" in the peer reviewed International Journal of Pathophysiology (DOI 10.1016/J.Pathophys.2004.06.001, http://www.sciencedirect.com/). The observational study, conducted by Benedict Maniscalco, M.D., F.A.C.C. of St. Joseph's Hospital, Tampa Florida, demonstrated a statistically significant reversal in the coronary artery calcium (CAC) scores of patients with stable coronary artery disease (CAD) taking Nanobac's proprietary comET nanobiotic regimen. CAC is the deposition of ...